NL-OMON50071
Completed
Not Applicable
Cellular & Serological Immune Response Monitoring in SARS-CoV2-infected individuals, without need of hospitalization - SARS-RESPONSE
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Corona virus
- Sponsor
- eids Universitair Medisch Centrum
- Enrollment
- 10
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject (male or female) tested positive for SARS\-CoV2 by PCR (nasal swab,
- •throat swab and/or sputum);
- •Subject is an adult of 18\-65 years old;
- •Subject is able to understand the PIF document, written in Dutch;
- •Subject is able to communicate well with the investigator in the Dutch
- •Subject signed informed consent prior to any study\-mandated procedure;
- •Subject is living in Leiden or direct environment (e.g. within 10 km from
- •LUMC), allowing for traveling by car, bike or by walking to LUMC (no public
- •transportation).
Exclusion Criteria
- •Subject tested negative upon SARS\-CoV2 PCR re\-analysis of nasal swab at
- •Subject previously fainted before, during or after a medical procedure with
- •Subject received plasma or other blood products during the previous 3 months;
- •Subject received a vaccination during the previous 3 months;
- •Subject is obese with BMI \>\=30, based on provide weight and length information;
- •Subject has a pre\-existing coagulopathy;
- •Subject uses medication for a coagulopathy;
- •Subject uses medication that suppresses the immune system;
- •Subject has an auto\-immune disease or another immune disease;
- •Subject has another infection in addition to the SARS\-CoV2 infection;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Monitoring response on COVID-19 vaccination in children with cancerChildren with cancer, receiving COVID-19 vaccinationTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2021-003388-90-NLPrincess Máxima Center for Pediatric Oncology130
Completed
Phase 4
Prospective monitoring of immune response following COVID-19 vaccination in children with cancerNL-OMON52106Prinses Máxima Centrum voor Kinderoncologie130
Recruiting
Not Applicable
Detection of markers for immune pathophysiology and analysis of their prognostic value in patients with chronic thrombocytopenia without an increase in the number of bone marrow megakaryocytes: a prospective observation study.Pancytopenia, thrombocytopeniaJPRN-UMIN000002729Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science.50
Recruiting
Phase 4
Evaluation of vaccine response to 13-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine in patients living with HIV/AIDSRBR-3wshg2mHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Recruiting
Not Applicable
Monitor immune microenvironment and systemic immune effects in pediatric oncologyNL-OMON52105Prinses Máxima Centrum voor Kinderoncologie300